ArticleScientific reports2021
Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Optical coherence tomography imaging biomarkers associated with neovascular age-related macular degeneration: a systematic review.Eye (London, England) · 2023Pooled it
- Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab.Journal of clinical medicine · 2026Article
- Risk of excessive macular thinning in diabetic macular edema with ellipsoid zone disruption treated with anti-VEGF: 2-year real-world evidence.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Automated Segmentation and Characterization of Retinal Hyperreflective Foci in Age-Related Macular Degeneration.Translational vision science & technology · 2026Article
- Choroidal Vascular Remodeling and Retinal Response After Aflibercept Loading in Diabetic Macular Edema.Ophthalmology science · 2026Article
- Article
- Hyperreflective Retinal Foci (HRF): Definition and Role of an Invaluable OCT Sign.Journal of clinical medicine · 2025Article
- Detection of diabetic macular oedema patterns with fine-grained image categorisation on optical coherence tomography.BMJ open ophthalmology · 2025Article
- Retinal Hyperreflective Foci Are Biomarkers of Ocular Disease: A Scoping Review With Evidence From Humans and Insights From Animal Models.Journal of ophthalmology · 2025Review
- Predictive value of hyperreflective foci for anti-VEGF therapeutic outcomes in different subtypes of diabetic macular edema: a retrospective analysis.Frontiers in endocrinology · 2025Article
- Study of Imaging Biomarkers as a Prognostic Factor and Guide in the Management of Diabetic Macular Oedema.Cureus · 2024Article
- Automatic Segmentation of Hyperreflective Foci in OCT Images Based on Lightweight DBR Network.Journal of digital imaging · 2023Article
- Angiographic biomarkers are significant predictors of treatment response to intravitreal aflibercept in diabetic macular edema.Scientific reports · 2023Article
- Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice.International journal of retina and vitreous · 2023Article
- Prognostic Imaging Biomarkers in Diabetic Macular Edema Eyes Treated with Intravitreal Dexamethasone Implant.Journal of clinical medicine · 2023Article
- Comparison of hyperreflective foci in macular edema secondary to multiple etiologies with spectral-domain optical coherence tomography: An observational study.BMC ophthalmology · 2022Observational
- Optical coherence tomography and imaging biomarkers as outcome predictors in diabetic macular edema treated with dexamethasone implant.Scientific reports · 2022Article
- Semi-Automated Quantification of Retinal and Choroidal Biomarkers in Retinal Vascular Diseases: Agreement of Spectral-Domain Optical Coherence Tomography with and without Enhanced Depth Imaging Mode.Diagnostics (Basel, Switzerland) · 2022Article
- Optical Coherence Tomography Angiography Characteristics Serve as Retinal Vein Occlusion Therapeutic Biomarkers for Dexamethasone Intravitreal Implant.Disease markers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.